{
  "_id": "84ac3b055945b3e1975b20e0d115a7538011e76b3ec48b12d8be48dbff7ae8b5",
  "feed": "wall-street-journal",
  "title": "Johnson & Johnson Posts Higher Quarterly Sales, Profit Despite Strong Dollar; Healthcare-products firm trims full-year sales outlook after foreign-exchange reduced quarterly sales by 6%",
  "text": "<p>For the third quarter, J&amp;J posted a quarterly profit of $4.46 billion, or $1.68 a share, up from $3.67 billion, or $1.37 a share, a year earlier. Adjusted for one-time costs, J&amp;J's per-share profit was $2.55. Wall Street analysts had been forecasting an adjusted profit of $2.48, according to FactSet.</p><p>The company cut its full-year sales guidance to a range of $93 billion to $93.5 billion, excluding sales from the company's Covid-19 vaccine. In July, J&amp;J guided for full-year sales of $93.3 billion to $94.3 billion.</p><p>J&amp;J narrowed its guidance for full-year operational sales, which also excludes the impact of currency-fluctuations, to a range of $97.5 billion to $98 billion.</p><p>Shares of J&amp;J rose more than 2% in premarket trading to $170.19. So far this year, the stock was down almost 3% as of Monday's closing price.</p><p>Write to Will Feuer at Will.Feuer@wsj.com</p><p>Johnson &amp; Johnson Posts Higher Quarterly Sales, Profit Despite Strong Dollar</p>",
  "published": "2022-10-18T11:07:00.000Z",
  "tags": [
    {
      "id": "US4781601046",
      "name": "Johnson & Johnson",
      "offsets": [
        {
          "start": 863,
          "end": 880
        },
        {
          "start": 0,
          "end": 17
        },
        {
          "start": 175,
          "end": 178
        },
        {
          "start": 689,
          "end": 692
        },
        {
          "start": 453,
          "end": 456
        },
        {
          "start": 23,
          "end": 26
        },
        {
          "start": 519,
          "end": 522
        }
      ],
      "nexusId": "10010560"
    }
  ]
}